Accurate Prostate Cancer Detection based on Circulating Tumor Cell Profiling
Rattachement africain : in, gb, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT Background Evaluation of serum prostate specific antigen (PSA) is a part of standard prostate cancer diagnostic work-up in symptomatic males as well as for elective prostate cancer screening in asymptomatic males. The low specificity of serum PSA leading to an inability to effectively differentiate prostate cancer from benign prostate conditions is a persistent clinical challenge. Further, the low sensitivity of serum PSA leading to false negatives can miss high-grade / aggressive prostate cancers. Objective We describe a non-invasive prostate cancer detection test based on functional enrichment of prostate adenocarcinoma associated circulating tumor cells (PrAD-CTCs) from blood samples and their identification via immunostaining for pan-cytokeratins (PanCK), prostate specific membrane antigen (PSMA), alpha methyl-acyl coenzyme-A racemase (AMACR), epithelial cell adhesion molecule (EpCAM) and common leucocyte antigen (CD45). Design, Setting, and Participants The analytical validation studies used VCaP reference prostate cancer cell line to evaluate the performance characteristics of the test. The clinical performance characteristics of the test were first evaluated in a case-control study with 160 known prostate cancer cases and 800 healthy males. A prospective clinical study was performed with samples from 210 suspected cases of prostate cancer. Outcome Measurements and Statistical Analysis Analytical validation established analyte stability as well as acceptable performance characteristics. The test showed 100% specificity and 100% sensitivity to differentiate prostate cancer cases from healthy individuals in the case control study and 91.2% sensitivity and 100% specificity to differentiate prostate cancers from benign prostate conditions in the prospective clinical study. Results and Limitations The test accurately detects PrAD-CTCs with high sensitivity and specificity irrespective of stage or grade (Gleason score), which translates into low risks of false negatives or overdiagnosis. The test does not detect minor non-adenocarcinoma subtypes of prostate cancer. Conclusions The high accuracy of the test offers advantages over PSA based prostate cancer detection.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Accurate Prostate Cancer Detection based on Circulating Tumor Cell Profiling
- Date Crossref
- 16/05/2022
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Sir H.N. Reliance Foundation Hospital and Research Centre pays non établi dans la noticeÉtablissement de santé
-
St Thomas' Hospital pays non établi dans la noticeÉtablissement de santé
-
King's College Hospital pays non établi dans la noticeÉtablissement de santé
-
Fortis Memorial Research Institute pays non établi dans la noticeÉtablissement de santé
-
Cancer Clinic pays non établi dans la noticeÉtablissement de santé
-
Hammersmith Hospital pays non établi dans la noticeÉtablissement de santé
-
Imperial College London John Fulcher Neuro-Oncology Laboratory pays non établi dans la noticeUniversité ou école supérieure
-
CancerCare Cape Town, Afrique du Sud (pays nommé en fin d’affiliation)Établissement de santé
-
Worcester Polytechnic Institute pays non établi dans la noticeUniversité ou école supérieure
-
Datar Cancer Genetics (India) pays non établi dans la noticeEntreprise
-
Sir HN Reliance Foundation Hospital and Research Centre pays non établi dans la noticeStructure de recherche
-
Sir HN Relince Foundtion Hospitl nd Reserch Centre pays non établi dans la noticeInstitution
Sir H.N. Reliance Foundation Hospital and Research Centre, St Thomas' Hospital et King's College Hospital, avec 9 autres affiliations. Pays d’affiliation : Afrique du Sud.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.